Another category of Russians who may be offered vaccination includes…
Another category of Russians who may be offered vaccination includes patients diagnosed with stage IB-IV skin melanoma who have not undergone any anti-tumor treatment.
Consensus
- The Russian personalized mRNA vaccine 'NEOONCOVAK' has been developed by the Gamaleya National Research Center and the Blokhin National Medical Research Center.
- The vaccine is being tested in clinical trials for treating melanoma.
- The first patient received the vaccine in April, and reports indicate positive immunological responses.
- The Ministry of Health granted approval for clinical use of the vaccine in May.
- The manufacturer of the vaccine is the National Medical Research Center of Radiology.
- Eligibility criteria include adults with non-resectable or metastatic melanoma, those who have undergone surgery with complete removal of metastases, patients with recurrent disease without brain metastases, and individuals newly diagnosed with stage IB-IV melanoma not yet receiving anti-tumor treatment.
Points of divergence
- The patient is continuing treatment with two more vaccinations using the drug produced at Gamaleya Institute and administered at Gertsen Institute. — vm
- On July 10, Russian scientists discovered that both types and strains of gut bacteria are important for predicting immunotherapy outcomes in melanoma patients. — vedomosti
- Alexander Ginzburg stated that the main immunological results will be expected after ten administrations of the drug. — kommersant
Coverage (4 sources)
- Russian vaccine against skin cancer successfully passed tests on first patient — Вечерняя Москва
- Adult patients in Russia will be able to use a vaccine for treating skin cancer — Ведомости
- Ministry of Health Clarifies Patient Categories for Melanoma Vaccine Application — Коммерсантъ
- Ministry of Health Defines Indications for Use of Russian Melanoma Vaccine — Вести
Key entities
- Ministry of Health
- NMI Center
- Russia
- RIA Novosti
- Moscow
- RAS
- Gamaleya Research Institute of Epidemiology and Microbiology
- Alexander Ginzburg
- Gamalei